EP3915576A1 — Chimeric antigen receptors specific for p95her2 and uses thereof
Assigned to Institucio Catalana de Recerca i Estudis Avancats ICREA · Expires 2021-12-01 · 4y expired
What this patent protects
The present invention relates to a chimeric antigen receptor (CAR) capable of targeting p95HER2-expressing cells. The invention also relates to a single-chain variable fragment (ScFv), to an antigen-binding domain and to an antibody or antibody fragment thereof capable of binding…
USPTO Abstract
The present invention relates to a chimeric antigen receptor (CAR) capable of targeting p95HER2-expressing cells. The invention also relates to a single-chain variable fragment (ScFv), to an antigen-binding domain and to an antibody or antibody fragment thereof capable of binding to the p95HER2 antigen. In addition, the present invention relates to an antibody-drug conjugate (ADC) comprising a therapeutic agent and an antibody or antigen-binding domain specific for p95HER2. The invention also relates to a method of cancer diagnosis and to a pharmaceutical composition for use in a method of preventing or treating cancer comprising the CAR and/or the antigen-binding domain or the antibody of the invention.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.